Nutriband Inc. (NTRB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
| Operating profit | $m | -8 | -7 | ||||||
| Net profit | $m | -3 | -8 | -5 | -5 | -10 | -8 | -7 | - |
| EPS reported | $ | -2.58 | -0.57 | ||||||
| Operating cashflow per share | $ | -0.44 | -0.36 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.44 | -0.36 | ||||||
| Free cash flow | $m | -5 | -4 | ||||||
| Net debt | $m | -4 | -3 | ||||||
| Book value equity | $m | 7 | 5 | ||||||
| Book value per share | $ | 0.57 | 0.44 | ||||||
| Number of shares | m | 11.64 | 12.16 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 13.16 | 16.50 | ||||||
| P/S LTM | x | 43.17 | 54.36 | ||||||
| P/FCF LTM | x | -17.13 | -24.21 | ||||||
| EV/EBITDA LTM | x | -10.46 | -12.31 | ||||||
| EV/Sales LTM | x | 25.25 | 20.16 | ||||||
| Earnings Yield LTM | % | -14.76% | -20.15% | ||||||
| FCF Yield | % | -5.84% | -4.13% | ||||||
| Quality | |||||||||
| ROE | % | -123.21% | -112.60% | ||||||
| ROIC | % | -1.20% | -1.31% | ||||||
| Operating margin | % | -4.08% | -4.53% | ||||||
| Gross margin | % | +27.81% | +28.35% | ||||||
| FCF/Sales | % | -252.11% | -241.62% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -4.83% | -24.41% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -20.92 | -18.66 | ||||||
| Net Debt/EBITDA | x | 0.54 | 0.48 | ||||||
| EBIT/Net interest | x | -369.11 | -376.62 | ||||||
| Net debt/market cap | % | +0.35% | +0.48% | ||||||
| Net debt/Equity | x | -0.66 | -0.62 | ||||||
| Gross debt/equity | x | 0.04 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free